Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 501–600 of 2,932
Epidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study
Alobaid, K., Ahmad, S., Asadzadeh, M., Mokaddas, E. M., Al‐Sweih, N., Benwan, K. A., Alfouzan, W. A., Al‐Obaid, I., Jeragh, A., Al-Roomi, E., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080673 · Cited by 35
“The highest incidence rate of 89.1 cases per 100,000 was detected among neonates/infants, followed by 62.46 cases per 100,000 for the elderly (≥65 years old) in Kuwait, while the data from the USA showed the highest incidence rate of 20.1 cases per 100,000 among the elderly [54].”
BackgroundInfluentialChen, J.-Z., Hu, N., Xu, H., Liu, Q., Yu, X., Zhang, Y., Huang, Y., Tan, J., Huang, X., & Zeng, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.721439 · Cited by 37
“6 million people worldwide have been reported to suffer from serious fungal diseases that have a profound impact on patients and can even be fatal (Bongomin et al., 2017).”
BackgroundInfluentialPaper and thread as media for the frugal detection of urinary tract infections (UTIs)
Hasandka, A., Singh, A., Prabhu, A., Singhal, H. R., Nandagopal, M. S. G., & Mani, N. K. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03671-3 · Cited by 32
“In addition to bacteria, fungi can also be pathogenic agents of UTI [11].”
BackgroundWillaert, R., Kayacan, Y., & Devreese, B. V. (2021) · Pathogens · doi:10.3390/pathogens10111397 · Cited by 27
“Early accurate diagnosis allows prompt antifungal therapy; this is, however, often delayed or unavailable leading to high mortality rates, serious chronic illness or blindness [1].”
BackgroundSathyapalan, D. T., Antony, R., Nampoothiri, V., Kumar, A., Shashindran, N., James, J., Thomas, J., Prasanna, P., Sudhir, A. S., Philip, J. M., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06131-6 · Cited by 34
In vivo imaging of invasive aspergillosis with 18F-fluorodeoxysorbitol positron emission tomography
Kim, D., Pyo, A., Ji, S., You, S.-H., Kim, S. E., Lim, D., Kim, H.-J., Lee, K., Oh, S.-J., Jung, Y.-R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29553-5 · Cited by 31
Yu, B., Li, C., Gu, L., Zhang, L., Wang, Q., Zhang, Y., Lin, J., Hu, L., Jia, Y., Yin, M., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174955 · Cited by 35
Charpak‐Amikam, Y., Lapidus, T., Isaacson, B., Duev‐Cohen, A., Levinson, T., Elbaz, A., Levi‐Schaffer, F., Osherov, N., Bachrach, G., Hoyer, L. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30087-z · Cited by 33
Hoy, M. J., Park, E., Lee, H., Lim, W. Y., Cole, D., DeBouver, N. D., Bobay, B. G., Pierce, P. G., Fox, D., Ciofani, M., et al. (2022) · mBio · doi:10.1128/mbio.01049-22 · Cited by 33
“Candida albicans, present a complicated treatment challenge (2).”
Hatmaker, E. A., Rangel‐Grimaldo, M., Raja, H. A., Pourhadi, H., Knowles, S. L., Fuller, K. K., Adams, E. M., Lightfoot, J. D., Bastos, R. W., Goldman, G. H., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03069-22 · Cited by 36
Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics
Inácio, M. M., Moreira, A. L. E., Cruz-Leite, V. R. M., Mattos, K., Silva, L. O. S., Venturini, J., Ruiz, O. H., Ribeiro‐Dias, F., Weber, S. S., Soares, C. M. D. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9060633 · Cited by 35
“5 million individuals, exceeding the number of deaths caused by malaria and being close to that of tuberculosis and the acquired immunodeficiency virus [1].”
BackgroundChanges in fungal taxonomy: mycological rationale and clinical implications
Borman, A. M., & Johnson, E. M. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00099-22 · Cited by 41
“Indeed, the annual burden of human disease was recently proposed to exceed 1 billion infections, with >150 million people suffering from serious fungal disease (7–9).”
BackgroundThe Burden of Fungal Diseases in Romania
Mareș, M., Moroti-Constantinescu, V. R., & Denning, D. W. (2018) · Journal of Fungi · doi:10.3390/jof4010031 · Cited by 28
“In light of current efforts being made worldwide to estimate the real importance and implications of fungi in human pathology, this epidemiological study aims to summarize essential information about the incidence and prevalence of serious fungal infections in Romania [2].”
BackgroundSelf-citationThe complement system in Aspergillus fumigatus infections and its crosstalk with pentraxins
Parente, R., Doni, A., Bottazzi, B., Garlanda, C., & Inforzato, A. (2020) · FEBS Letters · doi:10.1002/1873-3468.13744 · Cited by 36
Peterson, P. P., Choi, J.-T., Fu, C., Cowen, L. E., Sun, S., Bahn, Y.-S., & Heitman, J. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012735 · Cited by 25
Diagnosis from Tissue: Histology and Identification
Sabino, R., & Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8050505 · Cited by 35
“5 million deaths per year globally [7].”
Urease of Aspergillus fumigatus Is Required for Survival in Macrophages and Virulence
Xiong, Z., Zhang, N., Xu, L., Deng, Z., Limwachiranon, J., Guo, Y., Han, Y., Yang, W., & Scharf, D. H. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03508-22 · Cited by 33
Lin, S.-Y., Oakley, C. E., Jenkinson, C. B., Chiang, Y., Lee, C., Jones, C. G., Seidler, P. M., Nelson, H. M., Todd, R. B., Wang, C. C. C., et al. (2023) · Chemical Science · doi:10.1039/d3sc02226a · Cited by 31
Herculano, R. D., dos Reis, C. E., de Souza, S. M. B., Brasil, G. S. P., Scontri, M., Kawakita, S., de Carvalho, B. G., Bebber, C. C., Su, Y., Abreu, A. P. D. S., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.010 · Cited by 28
Chronic Pulmonary Aspergillosis: Clinical Presentation and Management
Evans, T. J., Lawal, A., Kosmidis, C., & Denning, D. W. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1776914 · Cited by 38
Self-citationCandida albicans N-Linked Mannans Potentiate the Induction of Trained Immunity via Dectin-2
Rosati, D., Pradhan, A., van Heck, J. I. P., Helder, L. S., Jaeger, M., Gow, N. A. R., Joosten, L. A. B., Williams, D. L., Brown, A. J. P., Bruno, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae112 · Cited by 30
Smith, D. J., Queiroz‐Telles, F., Rabenja, F. R., Hay, R. J., Bonifáz, A., Grijsen, M. L., Blaizot, R., Messina, F. A., Song, Y., Lockhart, S. R., et al. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012562 · Cited by 30
Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris
Carolus, H., Sofras, D., Boccarella, G., Jacobs, S., Biriukov, V. V., Goossens, L., Chen, A., Vantyghem, I., Verbeeck, T., Pierson, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01811-w · Cited by 31
George, M. E., Gaitor, T. T., Cluck, D. B., Henao‐Martínez, A. F., Sells, N. R., & Chastain, D. B. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251313841 · Cited by 72
“12,111 126 A 2021 survey conducted by the European Confederation of Medical Mycology assessed diagnostic capacities for invasive fungal infections across 45 European countries.”
Carrion, S. D. J., Abbondante, S., Clark, H., Marshall, M. E., Mouyna, I., Beauvais, A., Sun, Y., Taylor, P. R., Leal, S. M., Armstrong, B. A., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201847851 · Cited by 30
“The incidence of fungal infections has been increasing worldwide, especially those caused by Candida yeast and by filamentous fungi including Aspergillus fumigatus, which is ubiquitous in the environment [1, 2].”
BackgroundLam, P.-L., Wong, M., Hung, L.-K., Yung, L.-H., Tang, J. C. O., Lam, K. H., Chung, P. Y., Wong, W., Ho, Y.-W., Wong, R. S. M., et al. (2020) · Drug and Chemical Toxicology · doi:10.1080/01480545.2020.1778019 · Cited by 28
Bruno, M., Dewi, I. M. W., Matzaraki, V., ter Horst, R., Pekmezovic, M. G., Rösler, B., Groh, L. A., Röring, R. J., Kumar, V., Li, Y., et al. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.036 · Cited by 32
“000 lifethreatening invasive infections annually, with mortality rates ranging between 30 and 95% collectively [14,19].”
BackgroundMapping of Chronic Pulmonary Aspergillosis in Africa
Olum, R., Osaigbovo, I. I., Baluku, J. B., Stemler, J., Kwizera, R., & Bongomin, F. (2021) · Journal of Fungi · doi:10.3390/jof7100790 · Cited by 31
“CPA is increasingly being recognised as a global public health problem [5], with an estimated three million people affected, particularly those with underlying structural lung disease such as tuberculosis (TB), sarcoidosis, previous atypical mycobacterial infection, emphysema or those who have experienced a previous p…”
BackgroundSelf-citationEl-Sonbaty, M. M., Akl, M. A., El‐Say, K. M., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103096 · Cited by 28
El-Ganiny, A. M., Kamel, H. A., Yossef, N. E., Mansour, B., & El-Baz, A. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.01.011 · Cited by 30
“Fungal infections affect over a billion people worldwide, leading to high morbidity and mortality as well as expensive medical costs (Bongomin et al., 2017).”
BackgroundHu, W., Huang, L., Zhou, Z., Yin, L., & Tang, J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.743454 · Cited by 34
“Candida albicans is one of the most common commensal fungi in humans but causes millions of disseminated infections each year and can even cause death (Wisplinghoff et al., 2004; Bongomin et al., 2017; Pappas et al., 2018; Toda et al., 2019).”
BackgroundDevelopment of Lipo-γ-AA Peptides as Potent Antifungal Agents
Zhang, X., Wang, M., Zhu, X., Peng, Y., Fu, T., Hu, C., Cai, J., & Liao, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00595 · Cited by 34
Odiba, A. S., Durojaye, O. A., Ezeonu, I. M., Mgbeahuruike, A. C., & Nwanguma, B. C. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360973 · Cited by 33
“krusei.(4,9,10) The predominant cause of invasive fungal infection is C.”
The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance
Islam, M. R., Rahman, M. M., Islam, M. R., Sarkar, N., Akash, S., Islam, M., Islam, F., Aktar, M. N., Saeed, M., Harun-Or-Rashid, M., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22204-8 · Cited by 35
Gervais, N. C., Bella, A. A. L., Wensing, L. F., Sharma, J., Acquaviva, V., Best, M. A., López, R. O. C., Fogal, M., Uthayakumar, D., Chavez, A., et al. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac301 · Cited by 31
“albicans infections are becoming more prevalent globally, in part due to an increasing population of susceptible elderly and immunocompromised individuals (Bongomin et al. 2017).”
BackgroundInfluentialNanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections
Campos, L. D. A., Fin, M. T., dos Santos, K. S., Gualque, M. W. D. L., Cabral, A. K. L. F., Khalil, N. M., Fusco‐Almeida, A. M., Mainardes, R. M., & Mendes‐Giannini, M. J. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010266 · Cited by 33
“pergillosis reaches an estimated 3,000,000 cases per year of chronic pulmonary aspergillosis and 300,000 cases per year of IA [75].”
Background“Under Pressure” – How fungi evade, exploit, and modulate cells of the innate immune system
Lange, T., Kasper, L., Gresnigt, M. S., Brunke, S., & Hube, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101738 · Cited by 36
Intestinal bacteria—a powerful weapon for fungal infections treatment
Cong, L., Chen, C., Mao, S., Han, Z., Zhu, Z., & Li, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1187831 · Cited by 30
“Invasive fungal infections (IFI) are an increasingly serious public health problem, which can cause prominent invasive lesions with serious symptoms in the host, such as lifethreatening bloodstream infection and organ dysfunction (Bongomin et al., 2017).”
BackgroundNovel evidence on sepsis-inducing pathogens: from laboratory to bedside
Gatica, S., Fuentes, B., Rivera-Asín, E., Ramírez-Céspedes, P., Sepúlveda-Alfaro, J., Catalán, E. A., Bueno, S. M., Kalergis, A. M., Simón, F., Riedel, C. A., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1198200 · Cited by 41
The relevance of fungi in astrobiology research – Astromycology
Simões, M., Cortesão, M., Azúa-Bustos, A., Bai, F.-Y., Canini, F., Casadevall, A., Cassaro, A., Cordero, R., Fairén, A. G., González-Silva, C., et al. (2023) · Mycosphere · doi:10.5943/mycosphere/14/1/13 · Cited by 36
“According to the Leading International Fungal Education (LIFE, http://en.fungaleducation.org/) platform estimations, over 80% of the world’s population (more than 5.7 billion people) are affected by serious fungal infections (Bongomin et al. 2017).”
BackgroundInfluentialFDA‐approved drugs featuring macrocycles or medium‐sized rings
Du, Y., Semghouli, A., Wang, Q., Mei, H., Kiss, L., Baecker, D., Soloshonok, V. A., & Han, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400890 · Cited by 36
Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update
da Silva, L. B. B., Castilho, I. G., Silva, F. A. D. S., Ghannoum, M. A., Garcia, M. T., & do Carmo, P. H. F. (2025) · Microorganisms · doi:10.3390/microorganisms13061406 · Cited by 34
“In this context, superficial, cutaneous, and mucosal mycoses are highly prevalent, accounting for 1.1 million cases [2].”
InfluentialUnveiling the bioactive potential of the essential oil of a Portuguese endemism, Santolina impressa
Alves-Silva, J. M., Zuzarte, M., Gonçalves, M. J., Cruz, M. T., Cavaleiro, C., & Salgueiro, L. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112120 · Cited by 28
Wang, K., Luo, Y., Zhang, W., Xie, S., Yan, P., Liu, Y., Li, Y., Ma, X., Xiao, K., Fu, H., et al. (2019) · Mycoses · doi:10.1111/myc.13035 · Cited by 33
“Clinical performance of (1,3) beta-D-glucan for the diagnosis of Pneumocystis Pneumonia (PCP) in cancer patients tested with PCP polymerase chain reaction.”
MethodD’Ordine, R. L., Garcia, K. A., Roy, J., Zhang, Y., Markley, B., & Finkelman, M. (2020) · Medical Mycology · doi:10.1093/mmy/myaa028 · Cited by 29
Candida meningitis in neurosurgical patients: a single-institute study of nine cases over 7 years
Chen, M., Chen, C., Yang, Q., & Zhan, R. (2020) · Epidemiology and Infection · doi:10.1017/s0950268820001144 · Cited by 26
Structural basis of HapEP88L-linked antifungal triazole resistance in Aspergillus fumigatus
Hortschansky, P., Misslinger, M., Mörl, J., Gsaller, F., Bromley, M., Brakhage, A. A., Groll, M., Haas, H., & Huber, E. M. (2020) · Life Science Alliance · doi:10.26508/lsa.202000729 · Cited by 28
“The global burden of aspergillosis exceeds 14 million people and mortality rates are especially high in patients with chronic and invasive diseases (Bongomin et al, 2017).”
Antifungal polymers for medical applications
Velazco‐Medel, M. A., Camacho‐Cruz, L. A., Lugo‐González, J. C., & Bucio, E. (2020) · Medical Devices & Sensors · doi:10.1002/mds3.10134 · Cited by 28
“Some estimates indicate that the rate of fungal disease has surpassed at least one billion infections worldwide, with many strains of fungi causing hospital-related infections and high mortality rates on patients with compromised immune systems such as those with cancer, HIV-positive diagnoses (Bongomin et al., 2017;…”
BackgroundQadri, H., Qureshi, M. F., Mir, M. A., & Shah, A. H. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126725 · Cited by 28
Negm, W. A., El‐Aasr, M., Attia, G., Alqahtani, M. J., Yassien, R. I., Kamer, A. M. A., & Elekhnawy, E. (2022) · Journal of Fungi · doi:10.3390/jof8050426 · Cited by 28
“Labtech, FLUOstar Omega, Ortenberg, Germany), OD values were measured at 540 nm [31].”
BackgroundMa, J., Jiang, Y. Y., Zhuang, X., Chen, H., Shen, Y., Mao, Z., Rao, G.-X., & Wang, R. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128826 · Cited by 28
Zhang, Y., Wang, Y., Fan, J., Zhu, G., & Lü, L. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010976 · Cited by 27
“The limited repertoire of antifungal drug classes, the emergence of antifungal multidrug resistance and the toxicity caused by drugs negatively affect clinical outcomes and result in high rates of mortality and morbidity worldwide [2,3].”
BackgroundMammalian lipid droplets: structural, pathological, immunological and anti-toxicological roles
Hammoudeh, N., Soukkarieh, C., Murphy, D. J., & Hanano, A. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101233 · Cited by 27
Global knowledge gaps on antimicrobial resistance in the human health sector: A scoping review
Hamers, R. L., Dobreva, Z., Cassini, A., Tamara, A., Lazarus, G., Asadinia, K. S., Burzo, S., Olaru, I. D., Donà, D., Emdin, F., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.06.004 · Cited by 32
Diagnosing Emerging Fungal Threats: A One Health Perspective
Ghosh, P. N., Fisher, M. C., & Bates, K. A. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00376 · Cited by 30
The Cell Wall of Candida albicans: A Proteomics View
Reyna‐Beltrán, E., Bazán-Méndez, C. I., Iranzo, M., Mormeneo, S., & Luna‐Arias, J. P. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82348 · Cited by 31
“albicans is part of the normal microflora in humans and can be found in normal mucosae or cutaneous microflora of healthy individuals [2].”
BackgroundWeissman, Z., Pinsky, M., Donegan, R. K., Reddi, A. R., & Kornitzer, D. (2021) · Cellular Microbiology · doi:10.1111/cmi.13282 · Cited by 26
“It is the most prevalent systemic fungal pathogen, responsible yearly for close to a million cases with high (~40%) mortality (Kullberg and Arendrup, 2015; Bongomin et al., 2017).”
BackgroundChakrabarti, A., Patel, A. K., Soman, R. N., & Todi, S. K. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2257895 · Cited by 27
“Global Action Fund for Fungal Infection (GAFFI) estimated burden of serious fungal infections at 5.7 billion people after analyzing the country-wise data [13].”
BackgroundInfluentialMcCormick, T. S., & Ghannoum, M. A. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.656 · Cited by 37
Jiang, Z., Gai, W., Zhang, X., Zheng, Y., Jin, X., Han, Z., Ao, G., He, J., Shu, D., Liu, X., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1345706 · Cited by 32
Identification of an active RNAi pathway in Candida albicans
Iracane, E., Arias‐Sardá, C., Maufrais, C., Ene, I. V., d’Enfert, C., & Buscaino, A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315926121 · Cited by 28
Clinical aspects and recent advances in fungal diseases impacting human health
Pagano, L., & Fernández, O. M. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf004 · Cited by 47
Teasaponin suppresses Candida albicans filamentation by reducing the level of intracellular cAMP
Li, Y., Shan, M., Li, S., Wang, Y., Yang, H., Chen, Y., Gu, B., & Zhu, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.124 · Cited by 28
“Ann Transl Med 2020;8(5):175 | http://dx.”
BackgroundInhibitory effect of novel Eugenol Tosylate Congeners on pathogenicity of Candida albicans
Lone, S. A., & Ahmad, A. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-02929-0 · Cited by 32
Binjubair, F. A., Parker, J. E., Warrilow, A. G. S., Puri, K., Braidley, P. J., Tatar, E., Kelly, S. L., Kelly, D. E., & Simons, C. (2020) · ChemMedChem · doi:10.1002/cmdc.202000250 · Cited by 31
Bugeda, A., Garrigues, S., Gandía, M., Manzanares, P., Marcos, J. F., & Coca, M. A. (2020) · mSphere · doi:10.1128/msphere.00595-20 · Cited by 33
“F ungal infections threaten human health worldwide, causing the death of about 1.5 to 2 million people every year (1).”
InfluentialBorba-Santos, L. P., Vila, T. V. M., & Rozental, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240658 · Cited by 28
“Over the last 50 years, several fungal infections have emerged as important public health problems [20].”
BackgroundOpportunistic Invasive Fungal Infections Mimicking Progression of Non–Small-Cell Lung Cancer
Park, M., Ho, D. Y., Wakelee, H. A., & Neal, J. W. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.001 · Cited by 29
Aguieiras, M. C. L., Resende, L. M., Souza, T. A. M., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-020-09739-3 · Cited by 26
“Fungal diseases are estimated to affect more than one billion people worldwide, of whom 150 million suffer from serious infections [3, 4].”
BackgroundEpidemiology of Candidemia: Three-Year Results from a Croatian Tertiary Care Hospital
Mareković, I., Pleško, S., Vranješ, V. R., Herljević, Z., Kuliš, T., & Jandrlić, M. (2021) · Journal of Fungi · doi:10.3390/jof7040267 · Cited by 30
“However, knowing the local incidence, risk patient populations and species distribution is a basis for adequate management of candidemia, including empirical antifungal treatment, prophylaxis and infection prevention and control measures [7].”
BackgroundPreliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity
Duncan, V., Smith, D., Simpson, L., Lovie, E., Katvars, L., Berge, L., Robertson, J., Smith, S., Munro, C. A., Mercer, D., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02345-20 · Cited by 31
“comparable with that of tuberculosis and three times higher than that of malaria (1).”
ResultEnvironmental drivers of the seasonal exposure to airborne Alternaria spores in Spain
Picornell, A., Rojo, J., Trigo, M. M., Ruiz-Mata, R., Lara, B., Romero-Morte, J., Serrano-García, A., Pérez-Badía, R., Bustillo, M. G., Morales, P. C., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153596 · Cited by 29
Ma, X., Zhang, S., Xing, H., Li, H., Chen, J., Li, H., Jiao, M., Shi, Q., Xu, A., Xing, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.751617 · Cited by 26
“Sequencing the cfDNA of this microorganism can improve the possibility of non-invasive detection of multiple infections (17, 23, 24).”
BackgroundSouza, S. O., Raposo, B. L., Sarmento-Neto, J. F., Reboucas, J. S., Macêdo, D. P. C., de Figueiredo, R. C. B. Q., Santos, B. S., de Freitas, A. Z., Filho, P. E. C., Ribeiro, M. S., et al. (2022) · Journal of Fungi · doi:10.3390/jof8060556 · Cited by 31
“This fungus can be normally found as a commensal in the human oral and vaginal mucosa, gastrointestinal tract, and skin, but it can overgrow and cause infection, especially under immunocompromising conditions [2,3].”
BackgroundShahid, M., Hussain, A., Khan, A. A., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02219 · Cited by 26
Singh, A., Kaur, K., Kaur, H., Mohana, P., Arora, S., Bedi, N., Chadha, R., & Bedi, P. M. S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134456 · Cited by 31
Estimated burden of serious human fungal diseases in Turkey
Polat, S. H., Seyedmousavi, S., İlkit, M., Hedayati, M. T., İnci, R., Tümbay, E., & Denning, D. W. (2018) · Mycoses · doi:10.1111/myc.12842 · Cited by 29
Self-citationScordino, F., Giuffrè, L., Barberi, G., Marino‐Merlo, F., Orlando, M. G., Giosa, D., & Romeo, O. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00679 · Cited by 26
“Globally, invasive candidiasis affects more than 700,000 people worldwide every year and, with an unacceptably high mortality rate over 40%, is the cause of more than 280,000 deaths (Bongomin et al., 2017).”
BackgroundInfluentialWeissman, Z., Pinsky, M., Donegan, R. K., Reddi, A. R., & Kornitzer, D. (2020) · doi:10.1101/2020.07.26.221606 · Cited by 26
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 27
“…as well as those individuals suffering from severe respiratory viral infections (e.g., influenza and/or SARS-CoV-2) and the elderly (2–5, 48 Current antifungal agents cover most opportunistic fungal pathogens, including but not limited to C. albicans , A. fumigatus , and C.…”
BackgroundChen, P., Wu, H., Zhao, Y., Zhong, L., Zhang, Y., Zhan, X., Xiao, A., Huang, Y., Zhang, H., & Guan, B. (2024) · Advanced Materials · doi:10.1002/adma.202312985 · Cited by 31
Mo, H., Zhang, T., Zhang, J., Peng, S., Xiang, F., Li, H., Ge, Y., Yao, L., & Hu, L. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127704 · Cited by 27
Shahabudin, S., Azmi, N. S., Lani, M. N., Mukhtar, M., & Hossain, M. S. (2024) · Mycoses · doi:10.1111/myc.13753 · Cited by 49
“121,130 Diabetes is the leading risk factor for RVVC occurrence.”
BackgroundAhmed, S., Farag, M. M., Attia, H., Balkhi, B. S., Adel, I. M., & Nemr, A. A. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100322 · Cited by 25
AI in fungal drug development: opportunities, challenges, and future outlook
Li, Y., Qiao, Y., Ma, Y., Xue, P., & Ding, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1610743 · Cited by 42
Maciel, E. I., Jiang, C., Barghouth, P. G., Nobile, C. J., & Oviedo, N. J. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.12.005 · Cited by 26
“Candida albicans can lead to infections that range from superficial cutaneous and mucosal infections to severe systemic and invasive infections resulting in over 40% human mortality (Bongomin et al., 2017; Brown et al., 2012).”
El‐Bendary, M. A., Moharam, M. E., Abdelraof, M., Allam, M. A., Roshdy, A. M., Shaheen, M. N. F., Elmahdy, E. M., & Elkomy, G. M. (2019) · Archives of Microbiology · doi:10.1007/s00203-019-01718-9 · Cited by 26
Singh, R. P., Jaisingh, A., Maurya, I. K., & Salunke, D. B. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126869 · Cited by 25
Mourer, T., Ghalid, M. E., d’Enfert, C., & Bachellier‐Bassi, S. (2021) · Research in Microbiology · doi:10.1016/j.resmic.2021.103813 · Cited by 26
Sordarin— An anti‐fungal antibiotic with a unique modus operandi
Shao, Y., Molestak, E., Su, W., Stankevič, M., & Tchórzewski, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15724 · Cited by 27
“Pathogenic fungi are frequently called hidden killers (Brown et al., 2012), and approximately 1.5 million people lose their lives worldwide annually due to invasive mycoses (Kupferschmidt, 2019), while over 1 billion are exposed (Bongomin et al., 2017).”
BackgroundInfluentialPrajapati, J., Rao, P., Poojara, L., Goswami, D., Acharya, D., Patel, S., & Rawal, R. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.109048 · Cited by 30
Ball, B., Woroszchuk, E., Sukumaran, A., West, H., Afaq, A., Carruthers‐Lay, D., Muselius, B., Gee, L., Langille, M., Pladwig, S., et al. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02410-z · Cited by 25
“Furthermore, the frequency of invasive fungal infections is rapidly increasing due to growing numbers of immunocompromised individuals [1, 2].”
BackgroundCOVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Domán, M., & Bànyai, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919501 · Cited by 29
Imaging of Invasive Fungal Infections- The Role of PET/CT
Ankrah, A. O., Lawal, I. O., Dierckx, R., Sathekge, M. M., & Glaudemans, A. W. J. M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.07.003 · Cited by 30
Yerbanga, I. W., Diallo, S. N., Rouamba, T., Denis, O., Rodriguez‐Villalobos, H., Montesinos, I., & Bamba, S. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101328 · Cited by 26
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00415-3 · Cited by 29
“The majority of these infections are superficial and easy to treat, but roughly 150 million cases might be serious or life-threatening to individuals [4].”
BackgroundAntifungal stewardship: What we need to know
Ray, A., Das, A., & Panda, S. (2022) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_91_2022 · Cited by 29
Updated estimation of the burden of fungal disease in Vietnam
Duong, T. N., Le, M., Beardsley, J., Denning, D. W., Ngoc, H. L., & Nguyen, B. T. (2023) · Mycoses · doi:10.1111/myc.13559 · Cited by 27
“6 million deaths a year.(1) Identification of high- risk patients is an important initial step to reduce fungal infectionassociated mortality.”
BackgroundSelf-citationNasr, A. M., Badawi, N. M., Tartor, Y. H., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12040707 · Cited by 25
“Studies have shown that the greatest number of dermatological disorders occur as superficial fungal infections at a high rate in developing countries, and can in some cases lead to death [1].”
BackgroundYang, D., Zhang, M., Su, C., Dong, B., & Lü, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39284-w · Cited by 34
“We detected expression of 6281 C. albicans genes or roughly 98% of the predicted genome under at least one experimental condition (Supplementary Data 2).”
Influential
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.